Chabre O, Cristante J
Grenoble Alpes University Hospital (CHUGA) - Endocrinology, Grenoble, France.
Acta Endocrinol (Buchar). 2019 Apr-Jun;15(2):237-243. doi: 10.4183/aeb.2019.237.
Surgery plays a major role as a first-line treatment of the different etiologies of Cushing's syndrome (CS) and bilateral adrenalectomy (BA) is extremely effective as a second line, so that there seems to be little room for medical treatment (MT). However, during the past years several drugs acting either on ACTH secretion or cortisol synthesis have been developed, so that MT of CS might be reassessed. After briefly analyzing the efficiency and tolerance of surgical and medical treatments of CS we try to distinguish consensual and controversial indications for MT. We believe the former include "pre-operative treatment" in rare patients in whom the severity of CS is likely to increase the risks of surgery; "inoperability" for rare patients who cannot be operated even when CS is controlled and "surgical failure or recurrence", mainly in patients Cushing's disease (CD) not in remission after TSS. Controversial indications include "unavailability of an expert surgeon", which we believe does not make sense when the cost of MT is taken into consideration. Finally in patients with the "surgical failure or recurrence" indication the balance between efficacy and side effects of MT should be balanced with the efficacy and side effects of BA.
手术作为库欣综合征(CS)不同病因的一线治疗方法发挥着重要作用,双侧肾上腺切除术(BA)作为二线治疗极为有效,因此药物治疗(MT)似乎空间不大。然而,在过去几年中,已经开发出几种作用于促肾上腺皮质激素(ACTH)分泌或皮质醇合成的药物,因此可能需要重新评估CS的MT。在简要分析了CS手术和药物治疗的疗效及耐受性后,我们试图区分MT的共识性和争议性适应症。我们认为前者包括:在极少数CS严重程度可能增加手术风险的患者中进行“术前治疗”;在极少数即使CS得到控制也无法进行手术的患者中存在“无法手术”情况;以及“手术失败或复发”,主要是在经蝶窦手术(TSS)后未缓解的库欣病(CD)患者中。争议性适应症包括“缺乏专业外科医生”,我们认为在考虑MT成本时这一点毫无意义。最后,对于有“手术失败或复发”适应症的患者,MT的疗效和副作用之间的平衡应与BA的疗效和副作用相权衡。